# The first month of GLP-1 treatment: what early progress can look like

Early GLP-1 treatment involves tolerability and changing appetite. Long-term trial averages do not predict a first-month weight result.

Canonical: https://velri.co/blog/plus-size-first-month-glp1-realistic-expectations-marisol
Publisher: Velri (https://velri.co/about)
Published: 2026-07-21
Updated: 2026-09-30
Editorial policy: https://velri.co/editorial-policy

During the first month of GLP-1 weight treatment, follow-up focuses on appetite, side effects and how the prescribed plan is working. Weight response varies by medicine and by person. [1]

## Appetite and side effects are different observations

Semaglutide reduces calorie intake through effects that are likely related to appetite. Its prescribing information also lists gastrointestinal adverse effects, including nausea, vomiting, diarrhea and constipation. [2]

That means the early experience is worth describing precisely: a change in hunger, a change in meal intake and difficulty tolerating food are different observations. Persistent or severe symptoms should be reported to the prescribing clinician; vomiting or diarrhea can lead to dehydration and kidney injury. [2]

## The initial plan is built around tolerability

Approved semaglutide labeling uses a gradual increase during treatment initiation and allows changes when an increase is not tolerated. Any adjustment belongs with the prescribing clinician. [2]

The starting phase differs from longer-term treatment, so year-long study averages do not predict a first-month result.

## Look beyond one scale reading

NIDDK describes medication choice and continuation as a balance of benefit, side effects and individual circumstances. Medicines are used alongside nutrition and activity support, and outcomes differ between people. [1]

An early follow-up can therefore address several useful questions: what has changed in appetite and intake, which symptoms have occurred, whether the plan is practical, and what trend is emerging over time.

## Sources
[1] Prescription Medications to Treat Overweight & Obesity - NIDDK (2025). https://www.niddk.nih.gov/health-information/weight-management/prescription-medications-treat-overweight-obesity
[2] DailyMed - WEGOVY- semaglutide injection, solution
WEGOVY- semaglutide tablet (2026). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b

## About this information
General health information, not personal medical advice, diagnosis or treatment. A prescription is required and is never guaranteed.
Velri is a brand operated by Velri Management LLC, a Nevada limited liability company. Velri is a non-clinical technology and administrative services company. Velri does not provide medical advice, diagnosis, treatment, or pharmacy services, and does not direct the clinical judgment of any provider.
All medical consultations and prescriptions are provided directly by independent provider groups (Online Medical Care, P.C.; TMD of Kansas, P.A.; TMD of Texas, P.A.; and TMD of CA, PC), by a provider licensed in your state. Velri does not employ providers. A prescription is issued only if a provider determines it is clinically appropriate in their independent medical judgment.
All prescription products are dispensed by independent, licensed pharmacies. Velri does not own, operate, or control any pharmacy and does not dispense medication. You may opt out of using a given provider group or pharmacy at any time.
Compounded medications are not reviewed or approved by the FDA for safety, effectiveness, or quality. Compounded products are not equivalent to or interchangeable with any FDA-approved brand-name drug. Availability varies by state.
Velri is cash-pay. We do not bill Medicare, Medicaid, or commercial insurance. Refunds and order problems are addressed in the Terms of Use; your rights under applicable law are not limited. State availability and clinical eligibility apply.
Velri and telehealth are not for medical emergencies. If you are experiencing an emergency, call 911.
These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.
Care is available to eligible adults 18 and older in 47 states and D.C., United States only.
Notice of Privacy Practices: https://velri.co/privacy/notice-of-privacy-practices
Terms: https://velri.co/legal/terms
Provider group or pharmacy opt-out help: https://velri.co/contact and https://velri.co/standards#trust-support